Press Releases

afabicin (Debio 1450) afabicin (Debio 1450) ABSSSI afabicin (Debio 1450) Bone & joint infections CARB-X Clinical Trials CPP cyclosporin A Debio 0123 Debio 025 Debio 0507 Debio 0513 Debio 0517 Debio 0614 (istaroxime) Debio 0615 Debio 0617 Debio 0719 Debio 0824 Debio 0826 Debio 0827 Debio 0928 Debio 0929 Debio 0930 Debio 0931 Debio 0932 NSCLS Debio 0932 RCC Debio 1036 Debio 1124 Debio 1141 Debio 1142 Debio 1143 Debio 1143 Head & neck cancer Debio 1143 NSCLC Debio 1143 Ovarian cancer Debio 1144 Debio 1347 Debio 1348 Debio 1449 Debio 1453 Debio 1454 Debio 1460 Debio 1561 Debio 1562 Debio 8206 SC Debio 8609 Sanvar Debio 9902 - ZT-1 Debiopharm Life Sciences Award Debiovision EPFL EPI-hNE4 FibroTrap H3 Pharma Huperzine-A JCA-Mauvernay Award Moapar Muscular Dystrophy naratuximab emtansine (Debio 1562) Oncology Chair Oxaliplatin PLGA Spinomix Tremelimumab Triptorelin

February 14, 2019

Debiopharm International SA Initiates FUZE, a Clinical Trial Phase II study evaluating Debio 1347 in Advanced Solid Tumors harboring an…

January 7, 2019

Debiopharm Group regains the commercial rights to Trelstar® (Triptorelin pamoate) and looks for new partners in North America

October 11, 2018

Debiopharm International SA and the Paul Scherrer Institute announce a licensing agreement for the development of a novel targeted radiotherapeutic…

May 8, 2018

FDA Grants Fast Track designation to Debiopharm International’s Debio 1347 for the treatment of patients with unresectable or metastatic tumors…

November 22, 2017

Debiopharm International SA Launches Clinical Trials Website for Patients: patients.debiopharm.com

November 14, 2017

EMA grants Orphan Drug Designation to Debiopharm International SA’s FGFR inhibitor Debio 1347 in the treatment of biliary tract cancer

November 6, 2017

Debiopharm International SA Announces Dosing of First Patient in a Combination Trial of Debio 1143 and Avelumab in Patients with…

October 3, 2017

Arbor Pharmaceuticals, LLC and Debiopharm International SA Announce Commercial Availability of Triptodur™, Triptorelin 6-month Formulation, for Treatment of Central Precocious…

July 25, 2017

Debiopharm International SA Awarded $2.6 Million Grant from CARB-X to Support Development of Debio 1453 to fight drug resistant gonorrhea

First
Previous
1
2
…
21
Next
Last